Figure 1
Figure 2
Figure 3
Figure 4
![Local tumor recurrence-free rate according to the range of the embolization for transcatheter arterial chemoembolization (TACE). The cumulative 3-, 6-, 12-month tumor local recurrence rates were 2.8%, 2.8%, 8.3%, respectively, for cases with embolization of the entire corona enhancement area, and 20.8%, 45.8%, 75%, respectively, for cases without embolization of the entire corona enhancement area (hazard ratio [HR], 0.079; 95% confidence interval [CI], 0.026–0.24; p < 0.001).](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647356294e662f30ba53aaf0/j_raon-2021-0047_fig_004.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=AKIA6AP2G7AKOUXAVR44%2F20251204%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Date=20251204T150320Z&X-Amz-Expires=3600&X-Amz-Signature=31308154bb6beb2d425612ef782a1a345565726ac72a75e760b51859065fb11c&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)
Clinical characteristics of nodules in group A and B
| Clinical characteristics | Group A (n = 36) | Group B (n = 24) | p value |
|---|---|---|---|
| Age, years* | 74 (70–79) | 71 (64–79) | 0.149 |
| Gender, male/female | 8/28 | 6/18 | 0.999 |
| Etiology (HCV/HBV/Alcohol/Unknown) | 16/8/8/4 | 9/5/6/4 | 0.912 |
| Child-Pugh classification (A/B) | 31/5 | 19/5 | 0.569 |
| BCLC stage(0/A/B) | 11/20/5 | 5/17/2 | 0.545 |
| Size of tumor, mm* | 14.5 (12–21.3) | 15.5 (11–22) | 0.757 |
| Thickness of corona enhancement(≤ 2mm/>2mm) | 17/19 | 10/14 | 0.793 |
| AFP, ng/ml* | 4.9 (2.6–10.6) | 5.9 (2.7–14.1) | 0.419 |
| DCP, mAU/mL* | 26.4 (17.0–49.2) | 48.8 (25.3–153.9) | 0.021 |
| Usage of miriplatin, mg* | 28 (20–38.5) | 30 (22.4–51.5) | 0.310 |
Univariate and multivariate logistic regression analysis for factor affecting local tumor recurrence
| Factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
| Size of tumor (< 20 vs. ≥ 20 mm) | 0.67 (0.20–2.32) | 0.577 | ||
| AFP (< 10 vs. ≥ 10 ng/mL) | 0.45 (0.13–1.61) | 0.242 | ||
| DCP (< 40 vs. ≥ 40 mAU/mL) | 0.59 (0.18–1.92) | 0.417 | ||
| Usage of miriplatin (< 30 vs. ≥ 30 mg) | 0.70 (0.17–1.89) | 0.420 | ||
| Thickness of corona enhancement (≤ 2mm/ > 2mm) | 0.97 (0.30–3.20) | 0.999 | ||
| Degree of iodized oil accumulation (Group A vs. B) | 0.045 (0.0080–0.20) | < 0.001 | 0.042 (0.010–0.17) | < 0.001 |